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PURPOSE. To evaluate associations between conditions of ma-
ternal new-onset gestational hypertension (mHTN) and the
features imparting risk of severe retinopathy of prematurity
(ROP) in preterm infants.
METHODS. Hospital databases and charts of all preterm inborn
infants at the University of North Carolina from 1996 to 2007
were retrospectively reviewed. The presence or absence of
mHTN (e.g., pre-eclampsia) and infant factors (birthweight,
gestational age, erythropoietin use, and zone and stage of ROP)
were analyzed for independence of association.
RESULTS. Of the 5143 infants, 323 had ROP and 76 had mothers
with mHTN. Infants with ROP were more likely to have moth-
ers with mHTN and to be younger and smaller at birth. At initial
examination, more infants of mothers with mHTN had vascu-
larization into the lower zones than did infants of mothers
without mHTN (P  0.001). However, at the examination in
which the most severe ROP was present, there was no associ-
ation between mHTN and ROP stage (P  0.2342). Analysis of
stage and zone together showed that infants born to mothers
with mHTN were more likely to have ROP at initial examina-
tion, after adjustment for gestational age, but not for birth
weight. The use of erythropoietin was not associated with ROP
zone or stage, even after adjustment for maternal condition,
infant birth weight, or gestational age.
CONCLUSIONS. Although larger avascular areas or higher severity
scores were associated with mHTN after adjustment for gesta-
tional age at initial examination, no associations were found
between mHTN and ROP severity score at the examination
when ROP was most severe. There were no associations be-
tween ROP severity and treatment with erythropoietin. (Invest
Ophthalmol Vis Sci. 2010;51:4983–4988) DOI:10.1167/
iovs.10-5283
With the increase in preterm births in the United Statesand throughout the world, retinopathy of prematurity
(ROP) has become a leading cause of childhood blindness.1 It
has been recognized that young gestational age and low birth
weight are associated with greater risk of severe ROP and
blindness, and screening in the United States is thus recom-
mended for preterm infants born at less than 32 weeks’ gesta-
tional age or less than 1500 g birth weight.2 In recent studies,
however, the greater risk of severe ROP has been associated
with not only low birth weight, but also perinatal factors that
may lead to poor weight gain after birth.3
Conditions of maternal gestational hypertension include
pre-eclampsia, eclampsia, and HELLP syndrome (hypertension,
elevated liver enzymes, and low platelets). These clinically
significant obstetric complications are estimated to affect
nearly 5% of all pregnancies and represent a spectrum of
clinical signs that include new onset of maternal hypertension,
proteinuria, and edema.4 If not managed properly, these con-
ditions can progress to maternal seizures, antepartum hemor-
rhage, placenta abruption, coma or death, and premature fetal
delivery and/or death. Further, these conditions are associated
with low infant birth weight, and pre-eclampsia has been
independently associated with growth restriction.5 Recent
studies suggest that mothers with pre-eclampsia have elevated
levels of circulating antiangiogenic factors, such as the soluble
fms-like tyrosine kinase 1 (s-flt1)6 and endoglin (a co-receptor
of TGF1)7 and reduced levels of bioactive proangiogenic
factors, such as vascular endothelial growth factor (VEGF), and
placental growth factor (PIGF).8,9 In addition, prospective
studies have demonstrated that altered concentrations of an-
giogenic factors were sensitive predictors of pre-eclampsia.6
Since the intrauterine environment is essential for the devel-
oping fetus, uteroplacental insufficiency in conditions such as
pre-eclampsia may lead to altered fetal vascular programming
and both short- and long-term complications.
ROP develops after birth in preterm infants. Repeated lon-
gitudinal examinations of the infant fundus are performed to
detect either mature retinal vascularization or the development
of ROP. The area of retinal vascular development is defined as
the zone, with the lowest zone (zone I) being those with the
smallest area of vascularized retina and therefore, those with
the largest area of avascular retina. At initial examination,
retinal vascular development may be incomplete, with no ROP
present. However, as developmental angiogenesis proceeds,
ROP may manifest as different levels of disease severity.10 We
postulated that conditions of new-onset maternal hypertension
(including pre-eclampsia) may increase the severity of ROP by
interfering with the infant’s retinal vascular development, evi-
denced as a smaller zone at first examination, and thereby
increase the risk of severe ROP, evidenced by higher stage of
disease at the examination in which the most severe disease is
noted (“worst” examination).
To investigate, we evaluated associations between the pres-
ence of maternal gestational conditions of hypertension (pre-
eclampsia, eclampsia, or HELLP syndrome) and infant ROP.
The few studies in which these possible associations have been
investigated have reported conflicting conclusions.11,12 We
explored these relationships further in a sample of infants
larger than that studied in other efforts11,12 and born and cared
for at one institution. We also evaluated the effect of recombi-
nant erythropoietin, used for anemia of prematurity,13,14 since,
contradictory to recent clinical studies that report a positive
association of severe ROP with erythropoietin administra-
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tion,15,16 murine models of oxygen-induced retinopathy show
that erythropoietin has a protective effect if administered be-
fore a hyperoxic insult.17
METHODS
Design and Infant Data Collection
This clinical study was approved by the University of North Carolina
(UNC) at Chapel Hill School of Medicine’s Committee on the Protec-
tion of the Rights of Human Subjects and Institutional Review Board,
and all research adhered to the tenets of the Declaration of Helsinki.
This study was a retrospective review of hospital records for all
preterm infants born at UNC from April 1996 to October 2007. Only
infants born at 37 weeks’ gestation or less were screened for analysis,
since this is the maximum gestational age that most pregnancies are
allowed to reach before delivery if the mother has a maternal gesta-
tional condition of hypertension. Existing hospital databases from the
UNC Neonatal Critical Care Center (NCCC) and Labor and Delivery
Unit and infant medical records were reviewed.
Eye examinations in the UNC NCCC were performed, based on the
published screening recommendations for ROP,2 including screening
all infants born smaller than 1500 g or at a gestational age of 30 weeks
or less, as well as selected infants between 1500 and 2000 g birth
weight or a gestational age of more than 30 weeks who had an unstable
clinical course.2 In infants born earlier than or at 27 weeks’ gestation,
the initial examination was performed at 31 weeks’ postgestational
age. For infants older than 27 weeks’ gestational age, the initial exam-
ination was performed 4 weeks after birth. For infants with unstable
courses, the initial examination was sometimes postponed to 6 weeks
after birth. All screened infants had examinations performed before
discharge from the hospital.
For funduscopic examination, infants underwent pupillary dilation
with an ophthalmic solution of cyclopentolate and phenylephrine
(Cyclomydril; Alcon Laboratories, Forth Worth, TX) and indirect oph-
thalmoscopy with scleral depression at the bedside.2,10 Follow-up
examinations were based on the presence of ROP and performed as
recommended.10,18 The date and results of the examination in which
the most advanced ROP (highest stage) was observed that developed
during the infant’s course in the NCCC was designated the worst
examination.
The severity of ROP was based on the International Classification of
ROP (ICROP).19 The zone of ROP indicates the extent of intraretinal
vascularization that occurs during retinal vascular development. Zone
I comprised a circle centered on the optic nerve that had a radius equal
to twice the distance from the optic nerve to the fovea and had the
greatest area of avascular retina. Zone II was a circle centered on the
optic nerve, the radius of which equaled the distance from the optic
nerve to the nasal ora serrata, and zone III was the remaining temporal
crescent. For the purpose of analysis in this study, we expanded the
ICROP classification and designated eyes with mature vascularization
as zone IV. The stage of ROP reflected the level of severity of disease.
For analysis, we expanded the ICROP classification and designated no
ROP as stage 0. Stage 1 was a line; stage 2 a ridge; stage 3 intravitreous
neovascularization; and stages 4 and 5 incomplete and complete retinal
detachment, respectively.
Data from the initial examinations of the infants were collected
from their hospital charts, since the data were not available in the
NCCC database. Data from follow-up examinations were included in
the NCCC database and were used for abstracting data for the worst
examinations, except for three infants who met the screening criteria
but did not have recorded birth weights. Infant birth weight and
gestational age were common to both examinations. For the initial
examination, the ROP zone and stage of the eye with the lower zone
were recorded. For the worst examination, the zones and stages of
both eyes were reviewed, and the worse stage and lower zone of either
eye was recorded for each infant from hospital databases. Infants who
did not meet the criteria for ROP screening were assigned zone IV,
stage 0. Whether an infant had received erythropoietin treatment was
included with the data collected on the worst examination. Before
January 2004, infant oxygen saturations were kept between 98% and
100%, as best as possible, whereas after January 1, 2004, saturations
were maintained at 90% to 96% in infants less than 31 weeks’ postges-
tational age. Approximately 25% of the total number of study subjects,
and 31% of infants found to have the potential for ROP, were born after
2004 and were managed with these updated oxygen administration
protocols.
Data on maternal diagnosis was also obtained from the NCCC
database. Maternal care for new onset maternal gestational hyperten-
sion (pre-eclampsia, eclampsia, and HELLP syndrome) had been pro-
vided by the UNC neonatology teams as soon as the mothers were
identified. All infants studied were born at UNC.
Definitions of Variables
A dichotomous outcome variable was used to describe the presence or
potential to develop ROP versus the absence of ROP, for the descrip-
tive statistics. Infants were classified as having ROP if either eye had
stage 1 or greater ROP or had incomplete retinal vascularization,
(zone  IV). Only infants with stage 0 and zone IV ROP in both eyes
were grouped into the category of having no ROP. Therefore, some
infants with stage 0 ROP were grouped with those having ROP,
because they had the potential to develop ROP as long as their retinas
were incompletely vascularized. Infants were also categorized by
whether they had been born to mothers having a condition of new-
onset gestational hypertension (i.e., pre-eclampsia, eclampsia, or
HELLP syndrome) (yes/no) and whether they received erythropoietin
therapy (yes/no). Infant birth weight was categorized as follows: 700
g, 700 and 1000 g, and 1000 g. Gestational age was categorized
as 27 weeks versus 27 weeks.
Subsequent exploratory analyses were conducted with an ordinal
outcome variable that combined zone and stage into a ROP severity
score for each infant. The categories for this variable are presented in
Table 1. Having stage 0 and zone IV denoted the least severe, and
having stage 2 or 3 in either zone I or II denoted having the greatest
severity of ROP.
Statistical Analysis
Differences in percentages (or means) of birth weights or gestational
ages in each category were assessed between groups of infants with
and without ROP using binomial tests and t-tests. For assessing associ-
ations between the presence or absence of gestational hypertension or
previous erythropoietin therapy and the outcomes of zone, stage, and
the ROP severity score, Mantel-Haenszel raw mean score statistics were
calculated and 2 tests performed on these statistics. When considering
multivariate analyses, which adjusted for birth weight or gestational
age, Extended Mantel-Haenszel raw mean score statistics were used. In
calculating these statistics, modified ridit scores were used, because
the outcome categories were not thought to be equally spaced. All
tests were two-sided with   0.05 (SAS 9.2; SAS Institute, Cary, NC).
TABLE 1. Categorization of Stage and Zone into Ordinal ROP
Severity Variables
Stage 0
(no ROP) Stage 1 Stage 2 Stage 3
Zone IV (fully vascularized) 1 X X X
Zone III 2 2 2 2
Zone II 3 3 4 4
Zone I 3 3 4 4
Level 1 is least severe, and level 4 is most severe. X, no Zone IV
eyes had any stage of ROP by definition.
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RESULTS
During the study period, 4996 preterm infants where identified
as having an initial examination, and 5143 infants were identi-
fied as having a worst examination. At the time of their initial
examination, 176 (3.5%) of 4996 infants were classified as
having ROP. Of these 176 infants with ROP, 52 (29.5%) were
born to mothers with new-onset gestational hypertension that
included a diagnosis of preeclampsia, eclampsia, or HELLP
syndrome.
At the time of their worst examination, 323 (6.3%) of 5143
infants were classified as having ROP. Of these 323 infants with
ROP, 76 (24%) were born to mothers with new-onset gesta-
tional hypertension that included a diagnosis of preeclampsia,
eclampsia, or HELLP syndrome. The remaining 4820 infants
had fully vascularized retinas and were classified as not having
ROP (Table 2).
The majority of the infants, particularly infants with ROP,
were 30 weeks’ gestational age (73% of infants; data not
shown). Among mothers who had new-onset gestational hy-
pertension, the percentage of infants of gestational age 27
weeks was greater among infants with ROP than among those
without ROP at the initial examination (42% vs. 7%, P  0.001;
Table 2). Among mothers who did not have new-onset gesta-
tional hypertension, the percentage of infants with gestational
age 27 weeks was also greater among infants with ROP than
without ROP at the initial examination (67% vs. 8%, P  0.001).
In addition, mean gestational ages were lower in infants with
ROP than in those without at the initial examination, both in
infants from mothers with new-onset gestational hypertension
(28 vs. 32, P  0.001) and in infants from mothers without
gestational hypertension (27 vs. 33, P  0.001). Similar rela-
tionships were observed at the time of the worst examination
(Table 2).
Among mothers who had new-onset gestational hyperten-
sion, the percentage of infants with birth weight 700 g was
greater among infants with ROP than among those without
ROP at the initial examination (39% vs. 4%, P  0.001; Table 2).
Among mothers who did not have new-onset gestational hy-
pertension, the percentage of infants with birth weight 700
g was also greater among infants with ROP than without ROP
at the initial examination (20% vs. 3%, P  0.001). In addition,
mean birth weights were lower in infants with ROP than
without ROP at the initial examination for both infants from
mothers with new-onset gestational hypertension (823 g vs.
1725 g, P  0.001) and infants from mothers without gesta-
tional hypertension (948 g vs. 2145 g, P  0.001). A similar
relationship was observed for birth weights between 700 and
1000 g, as well as at the worst examination (Table 2).
To examine the effect of new-onset maternal gestational
hypertension on ROP severity, we first looked at whether
maternal hypertension was associated with lower zone at the
initial examination (Table 3). The percentages of infants with
lower zone tended to be slightly higher (e.g., 2% vs. 1% for
zone I, 3% vs. 2% for zone II) if they were born to mothers with
gestational hypertension than if they were born to mothers
without gestational hypertension (P  0.001). Statistical signif-
icance remained after adjustment for gestational age catego-
ries, with the association being stronger in infants 27 weeks
than in infants 27 weeks (data not shown). However, after
adjustment for birth weight categories, the association became
nonsignificant (P  0.2273). Examination of only those infants
TABLE 2. Characteristics of the Study Population
Initial Examination (n  4993) Worst Examination (n  5140)


















700 20 (39) 25 (20) 36 (4) 132 (3) 27 (36) 54 (22) 36 (4) 132 (3)
700 to 1000 22 (42) 57 (46) 94 (10) 205 (5) 36 (47) 117 (48) 94 (10) 205 (5)
1000 10 (19) 41 (33) 782 (86) 3569 (91) 13 (17) 75 (30) 782 (86) 3569 (91)
Mean (SD) 823 (291.41) 948 (276.60) 1725 (699.82) 2145 (798.41) 815 (264.80) 930 (305.39) 1725 (699.82) 2145 (798.41)
Initial Examination (n  4996) Worst Examination (n  5143)


















27 22 (42) 83 (67) 60 (7) 317 (8) 34 (45) 165 (67) 60 (7) 317 (8)
27 30 (58) 41 (33) 852 (93) 3591 (92) 42 (55) 82 (33) 852 (93) 3591 (92)
Mean (SD) 28 (2.44) 27 (2.40) 32 (2.92) 33 (3.49) 28 (2.00) 27 (2.53) 32 (2.92) 33 (3.49)
Erythropoietin received
Yes 14 (73) 37 (30) — — 22 (29) 67 (27) — —
No 38 (27) 87 (70) — — 54 (71) 180 (73) — —
Data are expressed as n (%), except where noted. mHTN, maternal new-onset gestational hypertension.
TABLE 3. Infants in Each Zone at Initial Examination by Maternal
New-Onset Hypertension Status
I II III IV Total
Hypertension 19 (2) 33 (3) 0 (0) 912 (95) 964
No hypertension 40 (1) 74 (2) 10 (0) 3908 (97) 4032
Data are expressed as frequencies (percentages) in each zone.
Unadjusted, P  0.001; after adjustment for birth weight categories,
P  0.2273; after adjustment for gestational age categories, P  0.001.
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32 weeks or 1500 g birth weight (n  1728) showed in a
similar distribution of zones: 89% for zone IV and maternal
hypertension versus 90% for zone IV and no maternal hyper-
tension. This association was not significant (P  0.3262; data
not shown).
At the time of the worst examination, we found there to be
no association between maternal hypertension and ROP stage
in infants who had zone  IV (P  0.2342, Table 4). There was
no statistical evidence for the association after adjustment for
gestational age (P  0.8237). However, after adjustment for
birth weight, marginal statistical significance was achieved
(P  0.0130), with the strength of the association between
maternal hypertension and ROP being primarily due to an
observed association in infants weighing 700 and 1000 g at
birth (data not shown).
We further explored the association between new-onset
maternal gestational hypertension and ROP severity by using a
severity score that combined zone and stage (Table 1). At the
time of the initial examination, we found there to be an asso-
ciation between gestational hypertension and ROP severity
(P  0.001). The association remained after adjustment for
gestational age, but no evidence of an association was found
after adjustment for birth weight (P  0.6786). Using the ROP
severity score at the time of the worst examination, we did not
find any evidence of an association between gestational hyper-
tension and ROP severity (P  0.2024) as well as after adjust-
ment for gestational age (P  0.6555) or birth weight (P 
0.2643).
Tables 5 and 6 display the percentages of infants in each
zone (for the initial examination) and with each ROP disease
stage (for the worst examination), by whether the infant re-
ceived erythropoietin therapy. Whereas there appeared to be a
slightly higher percentage of infants in zone I in the erythro-
poietin group compared with the group that did not receive
erythropoietin (16% vs. 10%), there was no evidence of an
overall association between erythropoietin treatment and zone
at the initial examination (P  0.3735). When the analysis was
limited to infants with zone  IV at the worst examination,
there was no evidence that erythropoietin therapy was associ-
ated with ROP disease stage (P  0.8478). When ROP severity
score was taken as the outcome, the lack of statistical associ-
ation persisted (P  0.8104). Adjustment for each of birth
weight, gestational age, and gestational hypertension alone did
not change the results appreciably (data not shown).
DISCUSSION
Uteroplacental insufficiency present in pregnant women with
pre-eclampsia, eclampsia, or HELLP syndrome may lead to
vascular compromise in the developing fetus.4,20 Few studies
have been performed to determine the associations of these
conditions with ROP severity, and the reports are conflicting.
Shah et al.11 reported that maternal pre-eclampsia was predic-
tive of ROP in very-low-birth weight infants, whereas Seiberth
and Linderkamp12 reported maternal pre-eclampsia was asso-
ciated with reduced incidence rates of ROP. Therefore, it
remains unclear if conditions of new-onset maternal hyperten-
sion affect the fetus’ developing retinal vasculature and lead to
ROP. To explore this, we reviewed all infants at our institution
who were born prematurely at 37 weeks of gestation over
the course of 11 years. Among them, we found a rare patient
cohort of 76 infants, revealing an incidence rate of approxi-
mately 7 infants per year.
In pre-eclampsia, maternal antiangiogenic factors have been
reported to be elevated and proangiogenic growth factors to
be reduced.4,21,22 One antiangiogenic factor that has been
studied is s-flt-1, a soluble splice variant of vascular endothelial
growth factor receptor 1 (VEGFR1). s-flt-1 can bind VEGF and
prevent it from signaling through its receptors.22 Some of the
symptoms associated with pre-eclampsia are similar to the side
effects reported from systemic inhibition of VEGF—namely,
hypertension, proteinuria, and vascular events.23 Angiogenesis
is necessary for fetal vasculogenesis, angiogenesis, and devel-
opment. Elevated maternal s-flt-1 could interfere with infant
development, including retinal vascular development, if s-flt-1
were to cross into the fetal circulation at an effective concen-
tration. In the retina, this may manifest as larger areas of
peripheral avascular retina (i.e., lower zones) on initial exam-
inations and higher stages and more severe ROP at later exam-
inations when ROP develops. It remains unclear to what extent
elevated maternal levels of antiangiogenic factors, including
s-flt-1, can cross through the placenta and into the fetal circu-
lation. Pregnant rodents treated with s-flt-1 as a means to model
manifestations of preeclampsia yielded mixed results.24–26 Off-
spring demonstrated mild growth retardation, but these effects
were limited to male mice, and treatment did not affect vascu-
lar patterning and development in neonatal mice.25 However,
lower concentrations of s-flt-1 may also have more profound
effects on retinal vessels, which are small and support a com-
plex, developing retinal structure, particularly in preterm in-
fants.
Postgestational age has been closely correlated with sever-
ity of ROP27 regardless of infant gestational age or birth weight.
Infants born at 27 weeks’ gestation or younger usually have
their first examinations performed at 31 weeks’ postgestational
age, whereas those born at or older than 28 weeks gestation
are examined at older ages, based on guidelines.2 Infants born
to mothers with conditions of new-onset gestational hyperten-
sion were more likely to have lower zones on initial examina-
tions than infants born to mothers without new-onset gesta-
tional hypertension. After adjustment for gestational age but
not birth weight, a significant association was still found be-
TABLE 4. Infants with Zone  IV in Each Stage ROP at Worst
Examination by Maternal New-Onset Hypertension Status
0 1 2 3 Total
Hypertension 3 (5) 25 (38) 27 (42) 10 (15) 65
No hypertension 12 (6) 55 (28) 88 (45) 40 (21) 195
Data are expressed as frequencies (percentages) at each stage.
Unadjusted, P  0.2342; after adjustment for birth weight categories,
P  0.0130; after adjustment for gestational age categories, P 
0.8237.
TABLE 6. Infants with Zone  IV in Each Stage ROP at Worst
Examination by Erythropoietin Therapy Status
0 1 2 3 Total
Erythropoietin 3 (4) 23 (32) 32 (45) 14 (19) 72
No erythropoietin 12 (7) 57 (30) 83 (44) 36 (19) 188
Data are expressed as frequencies (percentages) at each stage.
Unadjusted, P  0.8478.
TABLE 5. Infants in Each Zone at Worst Examination by
Erythropoietin Therapy Status
I II III IV Total
EPO 9 (10) 55 (62) 8 (9) 17 (19) 89
No EPO 38 (16) 135 (58) 15 (6) 46 (20) 234
Data are expressed as frequencies (percentages) in each zone.
Unadjusted, P  0.3735.
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tween greater infant severity score and maternal diagnosis of
new-onset gestational hypertension at the initial examination.
These results support the hypothesis that maternal conditions
leading to pre-eclampsia are associated with a greater potential
for infants to develop ROP. Still, it does not show an associa-
tion independent of low birth weight. However, at the worst
examination, no significant associations were found between
severity of ROP and maternal condition in unadjusted analyses
or analyses adjusted for birth weight or gestational age.
Recombinant erythropoietin has been used to treat anemia
of prematurity13,14 and has been associated with increased risk
of severe ROP.15,16 However, erythropoietin has also been
shown to reduce avascular retina if given before a hyperoxic
insult in a mouse model of oxygen-induced retinopathy.17
Therefore, we sought to determine whether there is an asso-
ciation between erythropoietin use and the severity of ROP in
infants born to mothers with new-onset gestational hyperten-
sion. However, we found no associations between the use of
erythropoietin and ROP severity, even after accounting for
maternal condition.
Other investigators have suggested that in response to a
hypoxic intrauterine environment from reduced levels of cir-
culating proangiogenic growth factors in pre-eclampsia, the
development of the fetal retinal vasculature may actually be
accelerated. Hadi and Hobbs28 demonstrated that when infants
are under chronic intrauterine stress, either from maternal
hypertension or pre-eclampsia, there is accelerated maturation
of the tunica vasculosa of the lens in the anterior compartment.
It was hypothesized that hypoxia-mediated stabilization of tran-
scription factors, such as hypoxia-inducible factor (HIF)-1, led
to increased fetal expression of molecules, such as VEGF,
erythropoietin, and glucose transporter-1.29 These and other
factors were then postulated to accelerate the maturation of
the retinal vasculature, thus reducing the potential for ROP to
develop. Our results at the time points of retinal examination
did not provide support for accelerated vascularization.
This was a retrospective study of a rare patient cohort of
infants with ROP born to mothers with new-onset gestational
hypertension. The low numbers of infants with ROP born to
mothers with new-onset gestational hypertension may have
limited the power of the analysis. Not all initial examination
records were accessible through existing databases and patient
hospital charts; however, care was taken to consider the anal-
yses of initial and worst examinations separately. ROP was
classified based on stages and zones abstracted from retinal
drawings without the benefit of wide-angle fundus imaging.
The study may also have had unrecognized confounding vari-
ables because of the long duration of the study period from
1996 to 2007, during which significant advances were made in
the screening and treatment algorithms for both maternal ges-
tational hypertension and infant ROP. One change was in
infant oxygen saturation. The number of infants born to moth-
ers with new-onset maternal hypertension in these subgroups,
defined by oxygen protocol, was too small for meaningful
analyses. The effect of oxygen should be addressed in larger
studies. All study participants were from a single tertiary cen-
ter, and therefore treatments of both new-onset maternal hy-
pertension and preterm infants were initiated at the time of
diagnosis, and little variability within the individual neonatol-
ogists’ practices was anticipated. Finally, our study grouped
maternal pre-eclampsia, eclampsia, and HELLP syndrome under
the same disease category to obtain a large enough study
sample for analysis. A more precise analysis would stratify
infants to each of these conditions; however, this would have
further limited the sample size and decreased the power.
In conclusion, the results of this study indicate that condi-
tions of new-onset maternal gestational hypertension, such as
pre-eclampsia, were associated with lower zone at initial ex-
aminations for ROP but were not associated with an increased
severity of ROP at the worst examination. Furthermore, the use
of erythropoietin did not have an effect on ROP severity, even
when maternal condition was considered. Future studies of
larger databases are needed and may provide greater insight
into the relationships of these maternal conditions and severity
of infant ROP.
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